Please Wait...

Serum Amyloid A (SAA)

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

SAA is an acute phase protein, mainly produced by the liver and released in response to inflammation or infections. Indeed, SAA production is stimulated by pro-inflammatory cytokines such as IL-6, IL-1 and TNF-α (Calabrò et al., 2010). SAA has a role in cholesterol metabolism as it circulates in low levels bound to High-Density Lipoprotein (HDL) (Coetzee et al., 1986). During inflammation, SAA levels strongly increase and the protein can constitute up to 80% of HDL apolipoproteins. SAA is also a precursor of amyloid A protein, an insoluble product whose pathological accumulation is named amyloidosis (Husebekk et al., 1985). Blood levels of SAA are increased in numerous inflammatory disorders including Rheumatoid Arthritis (Targonska-Stepniak and Majdan, 2014) .

Bioclinica Lab employs a manual sandwich immunoassay for the measurement of human SAA in serum.

Calabrò, P., Riegler, L., Limongelli, G., Maddaloni, V., Martone, F., Golia, E., D’Alessandro, R., Pacileo, G., Russo, M.G., Golino, P., et al. (2010). Production of Serum Amyloid a in Response to Inflammatory Cytokines by Human Adipocytes. Eur. J. Inflamm. 8, 99–105.

Coetzee, G.A., Strachan, A.F., van der Westhuyzen, D.R., Hoppe, H.C., Jeenah, M.S., and de Beer, F.C. (1986). Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. J. Biol. Chem. 261, 9644–9651.

Husebekk, A., Skogen, B., Husby, G., and Marhaug, G. (1985). Transformation of amyloid precursor SAA to protein AA and incorporation in amyloid fibrils in vivo. Scand. J. Immunol. 21, 283–287.

Targonska-Stepniak, B., and Majdan, M. (2014). Serum Amyloid A as a Marker of Persistent Inflammation and an Indicator of Cardiovascular and Renal Involvement in Patients with Rheumatoid Arthritis. Mediators Inflamm. 2014, e793628.

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Join Bioclinica in a live #Xtalks webinar 10/31 exploring challenges & benefits of different sourcing models to man… https://t.co/kRYNc1Z3gj
bioclinica (3 hours ago)
Bioclinica contributions toward advancement of #Alzheimer's disease research & therapies showcased in 8 different s… https://t.co/j96UN9568o
bioclinica (9 hours ago)
Bioclinica’s Joby John reflects on the #SCDM2018 Annual Conference & being a part a thriving community of clinical… https://t.co/c70gH5kJo9
bioclinica (Yesterday)
RT @bioclinica: Our own Jeff Heilbraun is in Tokyo nxt wk to lead a discussion at DIA’s Cardiac Safety Workshop in Japan. Jeff will give an…
bioclinica (Yesterday)
RT @Xtalks: Trends in #SitePayments: Insight into How CROs Can Gain a Competitive Edge This webinar will focus on the latest market researc…
bioclinica (Yesterday)
Great connecting w @bioclinica clients Odonate Therapeutics, Eisai, & PCI Biotech, at #ESMO18 #oncology… https://t.co/4wKrLof8e6
bioclinica (Yesterday)

Latest Blogs:

Dr. Joby John
Transformational Trends in Investigator Site Payments
Clinical Supply Chain Success: Leveraging Technology
Blood pressure monitor
Prescription box
Latin America: Benefit from the Right Partner